Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

EntroGen Inc
Profile last edited on: 9/21/13      CAGE: 58B27      UEI: MJ44NL19KCR7

Business Identifier: molecular diagnostics
Year Founded
2007
First Award
2012
Latest Award
2013
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

18750 Oxnard Street Suite 409
Tarzana, CA 91356
   (818) 342-2770
   info@entrogen.com
   www.entrogen.com
Location: Single
Congr. District: 30
County: Los Angeles

Public Profile

EntroGen is a biotechnology company with a primary focus on molecular diagnostics in the areas of hematology and oncology. EntroGen has a growing commercial portfolio of real-time PCR-based tests, with many of its products being used to guide and monitor targeted therapies for various malignancies. They currently offer the following products: Mutation Analysis Kits > ALK Resistance Mutation Analysis Kit > B-Raf Codon 600 Mutation Analysis Kit > B-Raf Mutation Analysis Kit > EGFR Mutation Analysis Kit > K-Ras Mutation Analysis Kit > K-Ras/B-Raf Mutation Analysis Kit Genotyping Kits > CYP2C9/VKORC1 Genotyping Kit > DPYD*2A Genotyping Kit > UGT1A1*28 Genotyping Kit Home | Contact Us | Privacy Policy

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$141,303
Phase II Dollars
$145,080
Total Awarded
$286,383

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2013 1 NIH $286,383
Project Title: Development of a Diagnostic Biomarker for Ewing's Sarcoma Family of Tumors.

Key People / Management

  Gary Potikyan

Company News

There are no news available.